RCS - Highlight Theraptcs. - Highlight to present at AACR

Merck & CoAnnouncement

15/03/2022 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220315:nRSO8076Ea&default-theme=true

RNS Number : 8076E  Highlight Therapeutics  15 March 2022

Highlight Therapeutics to present at the American Association for Cancer
Research (AACR) Annual Meeting 2022

 

Final results of SPOTLIGHT203 phase 2 study demonstrate new approach to second
line treatment for melanoma

 

Madrid, Spain, 15 March, 2022 - Highlight Therapeutics, ("Highlight"), a
clinical-stage biopharmaceutical company developing RNA-based therapies
against cancer, today announced an oral presentation at the Combination
Immunotherapy Clinical Trials Plenary Session at the American Association for
Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in
New Orleans, Louisiana. The Company will also present three posters.

 

 SESSION TITLE:       Combination Immunotherapy Clinical Trials
 PRESENTATION TITLE:  CT014

                      Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with
                      advanced melanoma refractory to anti-PD-1-based therapy: Final results of
                      SPOTLIGHT203 phase 2 study
 PRESENTER:           Ivan Marquez-Rodas
 DATE:                April 12, 2022
 TIME:                1015 -1215 PM CT
 LOCATION:            New Orleans Convention Center, Exhibit Halls B-C

 

Highlight will also present the following posters at AACR:

 

 PRESENTATION TITLE:  Correlation of biomarkers and clinical benefit of intratumoral BO112 and
                      pembrolizumab in patients with anti PD1 refractory melanoma
 DATE:                April 11, 2022
 TIME:                9:00 AM - 12:30 PM
 LOCATION:            New Orleans Convention Center

 

 PRESENTATION TITLE:  Radiomic features in tumor assessment, preliminary results from a phase 2
                      study of intratumoral administration of BO-112 with pembrolizumab in patients
                      with anti PD1 refractory melanoma
 DATE:                April 11, 2022
 TIME:                9:00 AM - 12:30 PM
 LOCATION:            New Orleans Convention Center

 

For more information, please contact:

 

 Highlight Therapeutics S. L.  info@highlighttherapeutics.com
 Marisol Quintero, CEO

 Mo PR Advisory                Tel: +44 (0) 7876 444977 / 07860 361746
 Mo Noonan/Jonathan Birt

 

Notes to editors

 

About Highlight Therapeutics

 

Highlight Therapeutics is a private, clinical-stage company dedicated to
unlocking the full potential of immuno-oncology. Our lead drug candidate
BO-112 is a best-in-class RNA-based therapy which has been demonstrated to
initiate a powerful immune response, leveraging a unique multi-target approach
to turn 'cold' tumors 'hot' and therefore visible to the immune system. It has
the potential to rescue patients who are resistant to current checkpoint
inhibitor therapy, a very large market opportunity. BO-112 is currently being
investigated in a range of clinical trials as a monotherapy and in combination
with checkpoint inhibitors. In addition to in-house research, Highlight
Therapeutics has a number of external collaborators, including Merck & Co
and UCLA.

 

For more information, please visit www.highlighttherapeutics.com
(http://www.highlighttherapeutics.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUQPWUPPURA